InvestorsHub Logo
Followers 0
Posts 846
Boards Moderated 0
Alias Born 07/10/2014

Re: Psychodad1620 post# 24528

Wednesday, 10/29/2014 9:53:35 PM

Wednesday, October 29, 2014 9:53:35 PM

Post# of 48316
As a monotherapy, PVCT has ONCS beat. The problem is that is as far as it goes for them. 25% (person, not lesion) CR is good, but they need a combination trial to be of any significance, along with serious monetary issues. Right now, I have no worries about PVCT beating ONCS, and have seen no evidence of any other competitor that has a chance of outdoing ONCS.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News